Assessment of tumor response to chemoradiotherapy and predicting prognosis in patients with head and neck squamous cell carcinoma by PERCIST
Purpose To evaluate therapeutic response to chemoradiotherapy and prediction of recurrence and death in patients with head and neck squamous cell carcinoma (HNSCC) using Positron Emission Tomography Response Criteria in Solid Tumors (PERCIST). Materials and methods Forty-two patients (mean 63.4, ran...
Gespeichert in:
| Veröffentlicht in: | Annals of nuclear medicine 2018-08, Vol.32 (7), p.453-462 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 462 |
|---|---|
| container_issue | 7 |
| container_start_page | 453 |
| container_title | Annals of nuclear medicine |
| container_volume | 32 |
| creator | Katsuura, Takayuki Kitajima, Kazuhiro Fujiwara, Masayuki Terada, Tomonori Uwa, Nobuhiro Noguchi, Kazuma Doi, Hiroshi Tamaki, Yukihisa Yoshida, Rika Tsuchitani, Tatsuya Fujita, Masahiro Yamakado, Koichiro |
| description | Purpose
To evaluate therapeutic response to chemoradiotherapy and prediction of recurrence and death in patients with head and neck squamous cell carcinoma (HNSCC) using Positron Emission Tomography Response Criteria in Solid Tumors (PERCIST).
Materials and methods
Forty-two patients (mean 63.4, range 20–79 years) with nasopharyngeal (
n
= 10), oropharyngeal (
n
= 13), hypopharyngeal (
n
= 11), or laryngeal (
n
= 8) cancer underwent fluorodeoxyglucose-positron emission tomography/computed tomography (FDG-PET/CT) before and approximately 3 months (mean 95.0, range 70–119 days) after undergoing concurrent chemoradiotherapy. The effect of PERCIST regarding progression-free survival (PFS) and overall survival (OS) was examined using log-rank and Cox methods.
Results
Complete metabolic response (CMR), partial metabolic response (PMR), stable metabolic disease (SMD), and progressive metabolic disease shown by PERCIST were seen in 30 (71.4%), 9 (21.4%), 3 (7.1%), and 0 patients, respectively. Fourteen (33.3%) developed recurrent disease (median follow-up 27.2, range 8.7–123.1 months) and 9 (21.4%) died (median follow-up 43.6, range 9.6–132.6 months). Furthermore, 4 (13.3%) of 30 patients with CMR developed recurrence, while 7 (77.8%) of 9 with PMR and all 3 (100%) with SMD developed recurrence. Two (6.7%) of 30 patients with CMR, 4 (44.4%) of 9 with PMR, and all 3 (100%) with SMD died. Patients who achieved CMR showed significantly longer PFS and OS as compared to those who did not (PMR and SMD) (both, p |
| doi_str_mv | 10.1007/s12149-018-1267-7 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2049560521</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2049560521</sourcerecordid><originalsourceid>FETCH-LOGICAL-c396t-89baaef10816efa1faa6784f7a9c15cd28f29c73995d638e92c54304ed5664be3</originalsourceid><addsrcrecordid>eNp1kcuKFDEUhoMoTjv6AG4k4MZNaW6Vy3JoRh0YUHRcF-nUqe6MXUlNThVDv4MPbdoeFQRXOSTf-fPDR8hLzt5yxsw75IIr1zBuGy60acwjsuJWq0YrKR-TFXNcNYZbc0aeId4yJmxrxVNyJlwdjDMr8uMCERBHSDPNA52XMRdaAKecEOicadhBvfJ9zPMOip8O1KeeTgX6GOaYtnXM25QxIo2JTn6ONQrpfZx3dAe-_4UnCN8p3i1-zAvSAPs9Db6EmPLo6eZAP19-WV99vXlOngx-j_Di4Twn395f3qw_NtefPlytL66bIJ2eG-s23sPAmeUaBs8H77WxajDeBd6GXthBuGCkc22vpQUnQqskU9C3WqsNyHPy5pRbu98tgHM3Rjy28glqwU4w5VrNWsEr-vof9DYvJdV2R8pqKSSXleInKpSMWGDophJHXw4dZ91RVXdS1VVV3VFVZ-rOq4fkZTNC_2fjt5sKiBOA9Sltofz9-v-pPwEqfqC6</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2048632313</pqid></control><display><type>article</type><title>Assessment of tumor response to chemoradiotherapy and predicting prognosis in patients with head and neck squamous cell carcinoma by PERCIST</title><source>MEDLINE</source><source>SpringerLink Journals</source><creator>Katsuura, Takayuki ; Kitajima, Kazuhiro ; Fujiwara, Masayuki ; Terada, Tomonori ; Uwa, Nobuhiro ; Noguchi, Kazuma ; Doi, Hiroshi ; Tamaki, Yukihisa ; Yoshida, Rika ; Tsuchitani, Tatsuya ; Fujita, Masahiro ; Yamakado, Koichiro</creator><creatorcontrib>Katsuura, Takayuki ; Kitajima, Kazuhiro ; Fujiwara, Masayuki ; Terada, Tomonori ; Uwa, Nobuhiro ; Noguchi, Kazuma ; Doi, Hiroshi ; Tamaki, Yukihisa ; Yoshida, Rika ; Tsuchitani, Tatsuya ; Fujita, Masahiro ; Yamakado, Koichiro</creatorcontrib><description>Purpose
To evaluate therapeutic response to chemoradiotherapy and prediction of recurrence and death in patients with head and neck squamous cell carcinoma (HNSCC) using Positron Emission Tomography Response Criteria in Solid Tumors (PERCIST).
Materials and methods
Forty-two patients (mean 63.4, range 20–79 years) with nasopharyngeal (
n
= 10), oropharyngeal (
n
= 13), hypopharyngeal (
n
= 11), or laryngeal (
n
= 8) cancer underwent fluorodeoxyglucose-positron emission tomography/computed tomography (FDG-PET/CT) before and approximately 3 months (mean 95.0, range 70–119 days) after undergoing concurrent chemoradiotherapy. The effect of PERCIST regarding progression-free survival (PFS) and overall survival (OS) was examined using log-rank and Cox methods.
Results
Complete metabolic response (CMR), partial metabolic response (PMR), stable metabolic disease (SMD), and progressive metabolic disease shown by PERCIST were seen in 30 (71.4%), 9 (21.4%), 3 (7.1%), and 0 patients, respectively. Fourteen (33.3%) developed recurrent disease (median follow-up 27.2, range 8.7–123.1 months) and 9 (21.4%) died (median follow-up 43.6, range 9.6–132.6 months). Furthermore, 4 (13.3%) of 30 patients with CMR developed recurrence, while 7 (77.8%) of 9 with PMR and all 3 (100%) with SMD developed recurrence. Two (6.7%) of 30 patients with CMR, 4 (44.4%) of 9 with PMR, and all 3 (100%) with SMD died. Patients who achieved CMR showed significantly longer PFS and OS as compared to those who did not (PMR and SMD) (both, p < 0.0001).
Conclusion
PERCIST is useful for evaluating therapeutic response to chemoradiotherapy and predicting recurrence and death in HNSCC patients.</description><identifier>ISSN: 0914-7187</identifier><identifier>EISSN: 1864-6433</identifier><identifier>DOI: 10.1007/s12149-018-1267-7</identifier><identifier>PMID: 29858797</identifier><language>eng</language><publisher>Tokyo: Springer Japan</publisher><subject>Adult ; Aged ; Carcinoma, Squamous Cell - diagnostic imaging ; Carcinoma, Squamous Cell - metabolism ; Carcinoma, Squamous Cell - mortality ; Carcinoma, Squamous Cell - therapy ; Chemoradiotherapy ; Chemotherapy ; Computed tomography ; Disease-Free Survival ; Female ; Fluorodeoxyglucose F18 ; Follow-Up Studies ; Head & neck cancer ; Head and Neck Neoplasms - diagnostic imaging ; Head and Neck Neoplasms - metabolism ; Head and Neck Neoplasms - mortality ; Head and Neck Neoplasms - therapy ; Humans ; Imaging ; Kaplan-Meier Estimate ; Male ; Medical prognosis ; Medicine ; Medicine & Public Health ; Metabolic disorders ; Metabolic response ; Middle Aged ; Neoplasm Recurrence, Local ; Nuclear Medicine ; Original Article ; Patients ; Positron emission ; Positron emission tomography ; Positron Emission Tomography Computed Tomography ; Predictions ; Prognosis ; Proportional Hazards Models ; Radiation therapy ; Radiology ; Radiopharmaceuticals ; Retrospective Studies ; Solid tumors ; Squamous cell carcinoma ; Squamous Cell Carcinoma of Head and Neck ; Survival ; Tomography ; Tumors ; Young Adult</subject><ispartof>Annals of nuclear medicine, 2018-08, Vol.32 (7), p.453-462</ispartof><rights>The Japanese Society of Nuclear Medicine 2018</rights><rights>Annals of Nuclear Medicine is a copyright of Springer, (2018). All Rights Reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c396t-89baaef10816efa1faa6784f7a9c15cd28f29c73995d638e92c54304ed5664be3</citedby><cites>FETCH-LOGICAL-c396t-89baaef10816efa1faa6784f7a9c15cd28f29c73995d638e92c54304ed5664be3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s12149-018-1267-7$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s12149-018-1267-7$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,776,780,27901,27902,41464,42533,51294</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/29858797$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Katsuura, Takayuki</creatorcontrib><creatorcontrib>Kitajima, Kazuhiro</creatorcontrib><creatorcontrib>Fujiwara, Masayuki</creatorcontrib><creatorcontrib>Terada, Tomonori</creatorcontrib><creatorcontrib>Uwa, Nobuhiro</creatorcontrib><creatorcontrib>Noguchi, Kazuma</creatorcontrib><creatorcontrib>Doi, Hiroshi</creatorcontrib><creatorcontrib>Tamaki, Yukihisa</creatorcontrib><creatorcontrib>Yoshida, Rika</creatorcontrib><creatorcontrib>Tsuchitani, Tatsuya</creatorcontrib><creatorcontrib>Fujita, Masahiro</creatorcontrib><creatorcontrib>Yamakado, Koichiro</creatorcontrib><title>Assessment of tumor response to chemoradiotherapy and predicting prognosis in patients with head and neck squamous cell carcinoma by PERCIST</title><title>Annals of nuclear medicine</title><addtitle>Ann Nucl Med</addtitle><addtitle>Ann Nucl Med</addtitle><description>Purpose
To evaluate therapeutic response to chemoradiotherapy and prediction of recurrence and death in patients with head and neck squamous cell carcinoma (HNSCC) using Positron Emission Tomography Response Criteria in Solid Tumors (PERCIST).
Materials and methods
Forty-two patients (mean 63.4, range 20–79 years) with nasopharyngeal (
n
= 10), oropharyngeal (
n
= 13), hypopharyngeal (
n
= 11), or laryngeal (
n
= 8) cancer underwent fluorodeoxyglucose-positron emission tomography/computed tomography (FDG-PET/CT) before and approximately 3 months (mean 95.0, range 70–119 days) after undergoing concurrent chemoradiotherapy. The effect of PERCIST regarding progression-free survival (PFS) and overall survival (OS) was examined using log-rank and Cox methods.
Results
Complete metabolic response (CMR), partial metabolic response (PMR), stable metabolic disease (SMD), and progressive metabolic disease shown by PERCIST were seen in 30 (71.4%), 9 (21.4%), 3 (7.1%), and 0 patients, respectively. Fourteen (33.3%) developed recurrent disease (median follow-up 27.2, range 8.7–123.1 months) and 9 (21.4%) died (median follow-up 43.6, range 9.6–132.6 months). Furthermore, 4 (13.3%) of 30 patients with CMR developed recurrence, while 7 (77.8%) of 9 with PMR and all 3 (100%) with SMD developed recurrence. Two (6.7%) of 30 patients with CMR, 4 (44.4%) of 9 with PMR, and all 3 (100%) with SMD died. Patients who achieved CMR showed significantly longer PFS and OS as compared to those who did not (PMR and SMD) (both, p < 0.0001).
Conclusion
PERCIST is useful for evaluating therapeutic response to chemoradiotherapy and predicting recurrence and death in HNSCC patients.</description><subject>Adult</subject><subject>Aged</subject><subject>Carcinoma, Squamous Cell - diagnostic imaging</subject><subject>Carcinoma, Squamous Cell - metabolism</subject><subject>Carcinoma, Squamous Cell - mortality</subject><subject>Carcinoma, Squamous Cell - therapy</subject><subject>Chemoradiotherapy</subject><subject>Chemotherapy</subject><subject>Computed tomography</subject><subject>Disease-Free Survival</subject><subject>Female</subject><subject>Fluorodeoxyglucose F18</subject><subject>Follow-Up Studies</subject><subject>Head & neck cancer</subject><subject>Head and Neck Neoplasms - diagnostic imaging</subject><subject>Head and Neck Neoplasms - metabolism</subject><subject>Head and Neck Neoplasms - mortality</subject><subject>Head and Neck Neoplasms - therapy</subject><subject>Humans</subject><subject>Imaging</subject><subject>Kaplan-Meier Estimate</subject><subject>Male</subject><subject>Medical prognosis</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Metabolic disorders</subject><subject>Metabolic response</subject><subject>Middle Aged</subject><subject>Neoplasm Recurrence, Local</subject><subject>Nuclear Medicine</subject><subject>Original Article</subject><subject>Patients</subject><subject>Positron emission</subject><subject>Positron emission tomography</subject><subject>Positron Emission Tomography Computed Tomography</subject><subject>Predictions</subject><subject>Prognosis</subject><subject>Proportional Hazards Models</subject><subject>Radiation therapy</subject><subject>Radiology</subject><subject>Radiopharmaceuticals</subject><subject>Retrospective Studies</subject><subject>Solid tumors</subject><subject>Squamous cell carcinoma</subject><subject>Squamous Cell Carcinoma of Head and Neck</subject><subject>Survival</subject><subject>Tomography</subject><subject>Tumors</subject><subject>Young Adult</subject><issn>0914-7187</issn><issn>1864-6433</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2018</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>8G5</sourceid><sourceid>BENPR</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNp1kcuKFDEUhoMoTjv6AG4k4MZNaW6Vy3JoRh0YUHRcF-nUqe6MXUlNThVDv4MPbdoeFQRXOSTf-fPDR8hLzt5yxsw75IIr1zBuGy60acwjsuJWq0YrKR-TFXNcNYZbc0aeId4yJmxrxVNyJlwdjDMr8uMCERBHSDPNA52XMRdaAKecEOicadhBvfJ9zPMOip8O1KeeTgX6GOaYtnXM25QxIo2JTn6ONQrpfZx3dAe-_4UnCN8p3i1-zAvSAPs9Db6EmPLo6eZAP19-WV99vXlOngx-j_Di4Twn395f3qw_NtefPlytL66bIJ2eG-s23sPAmeUaBs8H77WxajDeBd6GXthBuGCkc22vpQUnQqskU9C3WqsNyHPy5pRbu98tgHM3Rjy28glqwU4w5VrNWsEr-vof9DYvJdV2R8pqKSSXleInKpSMWGDophJHXw4dZ91RVXdS1VVV3VFVZ-rOq4fkZTNC_2fjt5sKiBOA9Sltofz9-v-pPwEqfqC6</recordid><startdate>20180801</startdate><enddate>20180801</enddate><creator>Katsuura, Takayuki</creator><creator>Kitajima, Kazuhiro</creator><creator>Fujiwara, Masayuki</creator><creator>Terada, Tomonori</creator><creator>Uwa, Nobuhiro</creator><creator>Noguchi, Kazuma</creator><creator>Doi, Hiroshi</creator><creator>Tamaki, Yukihisa</creator><creator>Yoshida, Rika</creator><creator>Tsuchitani, Tatsuya</creator><creator>Fujita, Masahiro</creator><creator>Yamakado, Koichiro</creator><general>Springer Japan</general><general>Springer Nature B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7QP</scope><scope>7RV</scope><scope>7TK</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FE</scope><scope>8FG</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>ARAPS</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BGLVJ</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>KB0</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M2O</scope><scope>M7P</scope><scope>MBDVC</scope><scope>NAPCQ</scope><scope>P5Z</scope><scope>P62</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>7X8</scope></search><sort><creationdate>20180801</creationdate><title>Assessment of tumor response to chemoradiotherapy and predicting prognosis in patients with head and neck squamous cell carcinoma by PERCIST</title><author>Katsuura, Takayuki ; Kitajima, Kazuhiro ; Fujiwara, Masayuki ; Terada, Tomonori ; Uwa, Nobuhiro ; Noguchi, Kazuma ; Doi, Hiroshi ; Tamaki, Yukihisa ; Yoshida, Rika ; Tsuchitani, Tatsuya ; Fujita, Masahiro ; Yamakado, Koichiro</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c396t-89baaef10816efa1faa6784f7a9c15cd28f29c73995d638e92c54304ed5664be3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2018</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Carcinoma, Squamous Cell - diagnostic imaging</topic><topic>Carcinoma, Squamous Cell - metabolism</topic><topic>Carcinoma, Squamous Cell - mortality</topic><topic>Carcinoma, Squamous Cell - therapy</topic><topic>Chemoradiotherapy</topic><topic>Chemotherapy</topic><topic>Computed tomography</topic><topic>Disease-Free Survival</topic><topic>Female</topic><topic>Fluorodeoxyglucose F18</topic><topic>Follow-Up Studies</topic><topic>Head & neck cancer</topic><topic>Head and Neck Neoplasms - diagnostic imaging</topic><topic>Head and Neck Neoplasms - metabolism</topic><topic>Head and Neck Neoplasms - mortality</topic><topic>Head and Neck Neoplasms - therapy</topic><topic>Humans</topic><topic>Imaging</topic><topic>Kaplan-Meier Estimate</topic><topic>Male</topic><topic>Medical prognosis</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Metabolic disorders</topic><topic>Metabolic response</topic><topic>Middle Aged</topic><topic>Neoplasm Recurrence, Local</topic><topic>Nuclear Medicine</topic><topic>Original Article</topic><topic>Patients</topic><topic>Positron emission</topic><topic>Positron emission tomography</topic><topic>Positron Emission Tomography Computed Tomography</topic><topic>Predictions</topic><topic>Prognosis</topic><topic>Proportional Hazards Models</topic><topic>Radiation therapy</topic><topic>Radiology</topic><topic>Radiopharmaceuticals</topic><topic>Retrospective Studies</topic><topic>Solid tumors</topic><topic>Squamous cell carcinoma</topic><topic>Squamous Cell Carcinoma of Head and Neck</topic><topic>Survival</topic><topic>Tomography</topic><topic>Tumors</topic><topic>Young Adult</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Katsuura, Takayuki</creatorcontrib><creatorcontrib>Kitajima, Kazuhiro</creatorcontrib><creatorcontrib>Fujiwara, Masayuki</creatorcontrib><creatorcontrib>Terada, Tomonori</creatorcontrib><creatorcontrib>Uwa, Nobuhiro</creatorcontrib><creatorcontrib>Noguchi, Kazuma</creatorcontrib><creatorcontrib>Doi, Hiroshi</creatorcontrib><creatorcontrib>Tamaki, Yukihisa</creatorcontrib><creatorcontrib>Yoshida, Rika</creatorcontrib><creatorcontrib>Tsuchitani, Tatsuya</creatorcontrib><creatorcontrib>Fujita, Masahiro</creatorcontrib><creatorcontrib>Yamakado, Koichiro</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Calcium & Calcified Tissue Abstracts</collection><collection>Nursing & Allied Health Database</collection><collection>Neurosciences Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Technology Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>Advanced Technologies & Aerospace Collection</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Technology Collection</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Research Library</collection><collection>Biological Science Database</collection><collection>Research Library (Corporate)</collection><collection>Nursing & Allied Health Premium</collection><collection>Advanced Technologies & Aerospace Database</collection><collection>ProQuest Advanced Technologies & Aerospace Collection</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><jtitle>Annals of nuclear medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Katsuura, Takayuki</au><au>Kitajima, Kazuhiro</au><au>Fujiwara, Masayuki</au><au>Terada, Tomonori</au><au>Uwa, Nobuhiro</au><au>Noguchi, Kazuma</au><au>Doi, Hiroshi</au><au>Tamaki, Yukihisa</au><au>Yoshida, Rika</au><au>Tsuchitani, Tatsuya</au><au>Fujita, Masahiro</au><au>Yamakado, Koichiro</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Assessment of tumor response to chemoradiotherapy and predicting prognosis in patients with head and neck squamous cell carcinoma by PERCIST</atitle><jtitle>Annals of nuclear medicine</jtitle><stitle>Ann Nucl Med</stitle><addtitle>Ann Nucl Med</addtitle><date>2018-08-01</date><risdate>2018</risdate><volume>32</volume><issue>7</issue><spage>453</spage><epage>462</epage><pages>453-462</pages><issn>0914-7187</issn><eissn>1864-6433</eissn><abstract>Purpose
To evaluate therapeutic response to chemoradiotherapy and prediction of recurrence and death in patients with head and neck squamous cell carcinoma (HNSCC) using Positron Emission Tomography Response Criteria in Solid Tumors (PERCIST).
Materials and methods
Forty-two patients (mean 63.4, range 20–79 years) with nasopharyngeal (
n
= 10), oropharyngeal (
n
= 13), hypopharyngeal (
n
= 11), or laryngeal (
n
= 8) cancer underwent fluorodeoxyglucose-positron emission tomography/computed tomography (FDG-PET/CT) before and approximately 3 months (mean 95.0, range 70–119 days) after undergoing concurrent chemoradiotherapy. The effect of PERCIST regarding progression-free survival (PFS) and overall survival (OS) was examined using log-rank and Cox methods.
Results
Complete metabolic response (CMR), partial metabolic response (PMR), stable metabolic disease (SMD), and progressive metabolic disease shown by PERCIST were seen in 30 (71.4%), 9 (21.4%), 3 (7.1%), and 0 patients, respectively. Fourteen (33.3%) developed recurrent disease (median follow-up 27.2, range 8.7–123.1 months) and 9 (21.4%) died (median follow-up 43.6, range 9.6–132.6 months). Furthermore, 4 (13.3%) of 30 patients with CMR developed recurrence, while 7 (77.8%) of 9 with PMR and all 3 (100%) with SMD developed recurrence. Two (6.7%) of 30 patients with CMR, 4 (44.4%) of 9 with PMR, and all 3 (100%) with SMD died. Patients who achieved CMR showed significantly longer PFS and OS as compared to those who did not (PMR and SMD) (both, p < 0.0001).
Conclusion
PERCIST is useful for evaluating therapeutic response to chemoradiotherapy and predicting recurrence and death in HNSCC patients.</abstract><cop>Tokyo</cop><pub>Springer Japan</pub><pmid>29858797</pmid><doi>10.1007/s12149-018-1267-7</doi><tpages>10</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0914-7187 |
| ispartof | Annals of nuclear medicine, 2018-08, Vol.32 (7), p.453-462 |
| issn | 0914-7187 1864-6433 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2049560521 |
| source | MEDLINE; SpringerLink Journals |
| subjects | Adult Aged Carcinoma, Squamous Cell - diagnostic imaging Carcinoma, Squamous Cell - metabolism Carcinoma, Squamous Cell - mortality Carcinoma, Squamous Cell - therapy Chemoradiotherapy Chemotherapy Computed tomography Disease-Free Survival Female Fluorodeoxyglucose F18 Follow-Up Studies Head & neck cancer Head and Neck Neoplasms - diagnostic imaging Head and Neck Neoplasms - metabolism Head and Neck Neoplasms - mortality Head and Neck Neoplasms - therapy Humans Imaging Kaplan-Meier Estimate Male Medical prognosis Medicine Medicine & Public Health Metabolic disorders Metabolic response Middle Aged Neoplasm Recurrence, Local Nuclear Medicine Original Article Patients Positron emission Positron emission tomography Positron Emission Tomography Computed Tomography Predictions Prognosis Proportional Hazards Models Radiation therapy Radiology Radiopharmaceuticals Retrospective Studies Solid tumors Squamous cell carcinoma Squamous Cell Carcinoma of Head and Neck Survival Tomography Tumors Young Adult |
| title | Assessment of tumor response to chemoradiotherapy and predicting prognosis in patients with head and neck squamous cell carcinoma by PERCIST |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-14T06%3A08%3A14IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Assessment%20of%20tumor%20response%20to%20chemoradiotherapy%20and%20predicting%20prognosis%20in%20patients%20with%20head%20and%20neck%20squamous%20cell%20carcinoma%20by%20PERCIST&rft.jtitle=Annals%20of%20nuclear%20medicine&rft.au=Katsuura,%20Takayuki&rft.date=2018-08-01&rft.volume=32&rft.issue=7&rft.spage=453&rft.epage=462&rft.pages=453-462&rft.issn=0914-7187&rft.eissn=1864-6433&rft_id=info:doi/10.1007/s12149-018-1267-7&rft_dat=%3Cproquest_cross%3E2049560521%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2048632313&rft_id=info:pmid/29858797&rfr_iscdi=true |